News | March 08, 2022
Industry upbeat on biopharma sector
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Data integrity early warning system assists pharmaceutical clients in proactively identifying and managing data integrity challenges in line with regulatory guidelines
Raising awareness about glaucoma is crucial in India where it is the leading cause of irreversible blindness with at least 12 million people affected and almost 1.2 million people blind from the disease
Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.
The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
With the implementation of this project, a total of 1,030 acres of cultivable land can be irrigated per crop cycle
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Subscribe To Our Newsletter & Stay Updated
